Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20333297
Mahajan K, et al. (2010) Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 5, e9646 20333297
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y284-p - Ack (human)
Modsite: LPQNDDHyVMQEHRK SwissProt Entrez-Gene
Orthologous residues
Ack (human): Y284‑p, Ack iso3 (human): Y347‑p, Ack (mouse): Y284‑p, Ack iso2 (mouse): Y284‑p, Ack (rat): Y284‑p
Associated Diseases
Diseases Alterations Comments
breast cancer increased

Y176-p - Akt1 (human)
Modsite: EKATGRYyAMKILKK SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): Y176‑p, Akt1 iso2 (human): Y114‑p, Akt1 (mouse): Y176‑p, Akt1 (rat): Y176‑p, Akt1 (fruit fly): Y292‑p, Akt1 (cow): Y176‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  breast, HEK293T (epithelial), MCF-7 (breast cell), RWPE1 (prostate cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heregulin increase
insulin increase
LY294002 heregulin no effect upon treatment-induced increase
Ack (human) increase Ack1 siRNA decreases
PIK3CA (human) no change compared to control PIK3CA siRNA- no change
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced, intracellular localization
Effect of modification (process):  cell cycle regulation, transcription, altered
Comments:  membrane localization
Associated Diseases
Diseases Alterations Comments
breast cancer increased

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  breast, MCF-7 (breast cell), RWPE1 (prostate cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heregulin increase
insulin increase
LY294002 heregulin inhibit treatment-induced increase
Ack (human) increase Ack siRNA decreases
PIK3CA (human) increase PI3CA siRNA decreases

Y284-p - Ack (mouse)
Modsite: LPQNDDHyVMQEHRK SwissProt Entrez-Gene
Orthologous residues
Ack (human): Y284‑p, Ack iso3 (human): Y347‑p, Ack (mouse): Y284‑p, Ack iso2 (mouse): Y284‑p, Ack (rat): Y284‑p

Y176-p - Akt1 (mouse)
Modsite: EKATGRYyAMKILKK SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): Y176‑p, Akt1 iso2 (human): Y114‑p, Akt1 (mouse): Y176‑p, Akt1 (rat): Y176‑p, Akt1 (fruit fly): Y292‑p, Akt1 (cow): Y176‑p
Characterization
Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Akt1 (mouse), heterozygous knockout], MEF (fibroblast) [Akt2 (mouse), homozygous knockout], prostate
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Ack (mouse)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Ack (mouse) mutation in upstream enzyme recognition motif, siRNA inhibition of enzyme, co-immunoprecipitation
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced, intracellular localization
Effect of modification (process):  cell cycle regulation, transcription, altered
Comments:  membrane localization
Associated Diseases
Diseases Alterations Comments
prostate cancer increased murine prostatic intraepithelial neoplasia (mPINs)

T308-p - Akt1 (mouse)
Modsite: KDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  prostate
Cellular systems studied:  cell lines
Species studied:  mouse

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Akt1 (mouse), heterozygous knockout], MEF (fibroblast) [Akt2 (mouse), homozygous knockout], prostate
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
LY294002 EGF inhibit treatment-induced increase